



Review decision

Review decision

Published: 12 June 2024

www.nice.org.uk

Decision to not review NICE's technology appraisal guidance for esketamine nasal spray for treatment-resistant depression

NICE's technology appraisal guidance on esketamine nasal spray for treatment-resistant depression (TA854) was published in December 2022. Esketamine nasal spray was not recommended, within its marketing authorisation, for treating treatment-resistant depression.

The initial review proposal was that an update was not needed. This was because the new evidence did not show a greater relative benefit with esketamine compared with current treatments than that considered in TA854. This proposal was consulted on with stakeholders.

The evidence received in the consultation did not support the need for an update of the existing recommendation.

So, the guidance will remain unchanged unless or until NICE becomes aware of new substantive information to support reconsideration. NICE will continue to monitor this topic for further evidence. It will also reconsider this decision if there are significant changes in the treatment pathway in the future (such as new treatments in the pathway).

[Review decision paper](#)